1-20 of 956 Search Results for

firm

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Image
Published: 01 April 2016
Figure 2 Trends in Average Firm R&D and SG&A Expenditures (in Millions of Dollars), 1999–2009 Source : Authors' analyses of data from firms' 10-K filings with the Securities and Exchange Commission, available in Mergent or Compustat, for firms with at least one NDA approval from More
Journal Article
J Health Polit Policy Law (2001) 26 (4): 798–803.
Published: 01 August 2001
... Matters: The Health Insurance Market for Small Firms. Brookfield, VT: Ashgate, 1999. 171 pp. $64.95 cloth. About one-half of firms with fewer than ten workers offer health insur- ance coverage to their workers. Forty-three million Americans lack health...
Image
Published: 01 April 2016
Figure 1 Trends in NDA Approvals for Publicly Traded Firms, 1999–2009 Source : Authors' analyses of data from Drugs@FDA for publicly traded firms. Complete description in “Data” section. Notes : NDAs=new drug applications; NME=new molecular entity Figure 1. Trends in NDA Approvals More
Journal Article
J Health Polit Policy Law (1996) 21 (4): 697–750.
Published: 01 August 1996
... five forms of community benefit that might be associated with nonprofit forms of managed care. Using data from a national survey of firms providing third-party utilization review services in 1993, we test for ownership-related differences in these five dimensions. The results suggest that ownership...
Journal Article
J Health Polit Policy Law (2019) 44 (5): 765–787.
Published: 01 October 2019
...” for DTCA as certified by firm executives. Methods: The authors measured recent industry spending on DTCA and used regression models of Nielsen Monitor-Plus data to assess pharmaceutical firm self-regulation after the public disclosure of noncompliance with industry self-regulatory principles, specifically...
FIGURES | View All (4)
Journal Article
J Health Polit Policy Law (1997) 22 (2): 557–593.
Published: 01 April 1997
... interventions at both the firm and public policy levels. Although currently enthusiastic about market–oriented managed care, large employers have been periodically disappointed by firm–level market experiments during the past two decades. They viewed with skepticism the Republican proposal to apply private...
Journal Article
J Health Polit Policy Law (2004) 29 (1): 11–42.
Published: 01 February 2004
... a very different relationship to firm-level quality, where firms within a chain that is being sued have higher levels of inspection-oriented quality. Our results suggest that legal claims may result from quality problems that go unmeasured during the inspection process. However, more research...
Journal Article
J Health Polit Policy Law (2020) 45 (5): 801–816.
Published: 01 October 2020
...-public option in which the government subcontracts the operation of its newly created plan to a private firm. Although it is uncertain whether federal regulators have the capacity to hold such private for-profit firms accountable, pragmatism suggests that a combination of public-sector regulation...
Journal Article
J Health Polit Policy Law (2016) 41 (2): 157–179.
Published: 01 April 2016
...Figure 2 Trends in Average Firm R&D and SG&A Expenditures (in Millions of Dollars), 1999–2009 Source : Authors' analyses of data from firms' 10-K filings with the Securities and Exchange Commission, available in Mergent or Compustat, for firms with at least one NDA approval from...
FIGURES
Journal Article
J Health Polit Policy Law (2014) 39 (5): 989–1012.
Published: 01 October 2014
... of the worker both represent a productivity-enhancing investment in the worker by the firm. The problem is that the employer frequently fails to capture the returns on the investment. A healthier or better-skilled worker can command a higher wage and threaten to leave the firm making the investment. This risk...
Image
Published: 01 October 2020
Figure 7 Trends in offer rates for employer-sponsored insurance coverage, by workers' firm size, 2014–2018. Notes : Analysis limited to workers aged 19–64 years. Source : Annual Social and Economic Supplement of the Current Population Survey 2014–2018. Figure 7 Trends in offer rates More
Image
Published: 01 April 2016
Figure 3 Estimated Impact of Increased Lagged and Current SG&A and R&D on NDA Approvals Source : Authors' analyses of data for publicly traded firms with complete financial data, as described in the “Data” section. Notes : R&D=research and development; SG&A=selling, general More
Journal Article
J Health Polit Policy Law (2009) 34 (6): 1035–1077.
Published: 01 December 2009
...” regimes do), performance-based regulation allows the firms to determine how best to decrease bad public health consequences. Like other public health strategies, performance-based regulation focuses on those who are far more likely than individual consumers to achieve real gains. Analogous to a tax...
Journal Article
J Health Polit Policy Law (2006) 31 (3): 511–529.
Published: 01 June 2006
... and heterogeneity of local health care markets, it advises courts not to accept the FTC's preemptive standard regarding the significance of hospitals' nonprofit status and keep open the possibility of fashioning new presumptive rules tailored to more complete economic accounts of nonprofit firm behavior. Duke...
Journal Article
J Health Polit Policy Law (2010) 35 (3): 407–422.
Published: 01 June 2010
...Michael Birnbaum Michael Birnbaum interviews Deborah Bachrach about her three-year tenure as director of the nation's largest Medicaid program. Bachrach, who served under Governors Spitzer and Paterson, had previously spent over a decade as a partner in a New York law firm, navigating and shaping...
Journal Article
J Health Polit Policy Law (1995) 20 (4): 973–1000.
Published: 01 August 1995
..., despite several recent interruptions in vaccine production and supply. Moreover, the increasing producer concentration in the U.S. and global vaccine industries raises the possibility that more and more important vaccines will be produced by a single firm, often in a single production facility...
Journal Article
J Health Polit Policy Law (1997) 22 (2): 509–532.
Published: 01 April 1997
... firms. I suggest that we cannot understand managed care unless we understand its power as at least substantially due to its reliance on a claim to be better science. In this way, managed care needs to be placed within an analytic historical tradition that is concerned with how accounts of scientific...
Journal Article
J Health Polit Policy Law (2008) 33 (1): 93–115.
Published: 01 February 2008
... services, the government's program was a hastily implemented attempt to place primary care, the delivery of which is dominated by private doctors, under firm state control. It was also an attempt to override preexisting arrangements. As such, the government succeeded in its goal of establishing new primary...
Journal Article
J Health Polit Policy Law (2008) 33 (3): 429–453.
Published: 01 June 2008
.../commercial product mix; (2) attracting nonresidents to use the community's retail and public space; and (3) capitalizing on community investment not simply from residents' organizing efforts but, more important in this case, from corporate community involvement by a Greendale business firm whose interests...
Journal Article
J Health Polit Policy Law (1992) 17 (3): 439–462.
Published: 01 June 1992
... and premiums are not distinct entities; rather, a spectrum of financing methods exists with varying tax-like and premium-like features. Premium-like financing tends to be voluntary and earmarked for health care, with coverage contingent upon making payments and payments going to private insurance firms. Tax...